https://www.pnas.org/content/116/37/18528
https://www.ncbi.nlm.nih.gov/pubmed/31455731?dopt=Abstract
Modulating REV-ERBα activity may be used to manipulate Th17 cells in autoimmune diseases such as multiple sclerosis
Related Articles
The nuclear receptor REV-ERBα modulates Th17 cell-mediated autoimmune disease.
Proc Natl Acad Sci U S A. 2019 Aug 27;:
Authors: Chang C, Loo CS, Zhao X, Solt LA, Liang Y, Bapat SP, Cho H, Kamenecka TM, Leblanc M, Atkins AR, Yu RT, Downes M, Burris TP, Evans RM, Zheng Y
Abstract
T helper 17 (Th17) cells produce interleukin-17 (IL-17) cytokines and drive inflammatory responses in autoimmune diseases such as multiple sclerosis. The differentiation of Th17 cells is dependent on the retinoic acid receptor-related orphan nuclear receptor RORγt. Here, we identify REV-ERBα (encoded by Nr1d1), a member of the nuclear hormone receptor family, as a transcriptional repressor that antagonizes RORγt function in Th17 cells. REV-ERBα binds to ROR response elements (RORE) in Th17 cells and inhibits the expression of RORγt-dependent genes including Il17a and Il17f Furthermore, elevated REV-ERBα expression or treatment with a synthetic REV-ERB agonist significantly delays the onset and impedes the progression of experimental autoimmune encephalomyelitis (EAE). These results suggest that modulating REV-ERBα activity may be used to manipulate Th17 cells in autoimmune diseases.
PMID: 31455731 [PubMed – as supplied by publisher]